Población estudiantil universitaria: percepción sobre la modalidad de clases en contexto de la COVID-19

The effects on different human groups caused by social isolation due to the SARS-CoV-2 pandemic are currently being known. In this context, one of the least favored sectors and that even until the end of 2021 had not resumed activities to a great extent of Latin America was the education sector and, in the face of a new variant of the virus, it is possible that these activities will continue virtually in 2022. In this regard, the present study aims to show the appreciation of the students, mainly university students, in order to know the perception and assessment regarding the class modality types in the context of COVID-19. For this, a quantitative and descriptive study was designed based on the interpretation of information obtained from surveys carried out on 198 students from the National University of San Cristóbal de Huamanga in Peru. The results regarding the qualification of learning in the virtual modality of the theoretical classes show that 58.1% of students mention that it was regular and 31.3% that it was good, regarding learning in the virtual modality of the experimental classes, 43.4% mention that it was regular and 38.9% deficient. Their preferences in most cases is to have theoretical classes virtually and/or blended; and experimental laboratory classes in face to face and/or blended; Likewise, under the current context of COVID-19, 85.4% of students state that they prefer their health over their professional training.Actualmente se están conociendo los efectos sobre los diferentes grupos humanos ocasionados por el aislamiento social debido a la pandemia del SARS-CoV-2. En este contexto uno de los sectores menos favorecidos y que aún hasta finales del 2021 no había retomado las actividades en gran parte de América Latina fue el sector educativo y, ante una nueva variante de virus es posible que continúe de forma virtual el 2022. En ese sentido, el presente estudio tiene como objetivo mostrar cual es la apreciación de los estudiantes, principalmente universitarios, a fin de conocer la percepción y valoración respecto a la modalidad de clases en contexto de COVID-19. Para ello se diseñó un estudio tipo cuantitativo y descriptivo basado en la interpretación de información obtenida de encuestas realizadas a 198 estudiantes de la Universidad Nacional de San Cristóbal de Huamanga en Perú. Los resultados respecto a la calificación del aprendizaje en la modalidad virtual de las clases teóricas muestran que el 58,1% de estudiantes mencionan que fue regular y el 31,3% que fue buena; respecto al aprendizaje en la modalidad virtual de las clases experimentales el 43,4% menciona que fue regular y 38,9% deficiente. La preferencia en la mayoría de los casos es tener clase teóricas de forma virtual y/o semipresencial y clases de laboratorio experimentales de forma presencial y/o semipresencial. Asimismo, bajo el contexto actual de la COVID-19 un 85,4% de estudiantes manifiesta preferir su salud por encima de su formación profesional

High exposure to tacrolimus is associated to spontaneous remission of recurrent membranous nephropathy after kidney transplantation

Introduction We aimed to characterize the incidence and clinical presentation of membranous nephropathy (MN) after kidney transplantation (KT), and to assess allograft outcomes according to proteinuria rates and immunosuppression management. Methods Multicenter retrospective cohort study including patients from six Spanish centers who received a KT between 1991-2019. Demographic, clinical, and histological data were collected from recipients with biopsy-proven MN as primary kidney disease (n = 71) or MN diagnosed de novo after KT (n = 4). Results Up to 25.4% of patients with biopsy-proven MN as primary kidney disease recurred after a median time of 18.1 months posttransplant, without a clear impact on graft survival. Proteinuria at 3-months post-KT was a predictor for MN recurrence (rMN, HR 4.28; P = 0.008). Patients who lost their grafts had higher proteinuria during follow-up [1.0 (0.5-2.5) vs 0.3 (0.1-0.5) g/24 h], but only eGFR after recurrence treatment predicted poorer graft survival (eGFR < 30 ml/min: RR = 6.8). We did not observe an association between maintenance immunosuppression and recurrence diagnosis. Spontaneous remission after rMN was associated with a higher exposure to tacrolimus before recurrence (trough concentration/dose ratio: 2.86 vs 1.18; P = 0.028). Up to 94.4% of KT recipients received one or several treatments after recurrence onset: 22.2% rituximab, 38.9% increased corticosteroid dose, and 66.7% ACEi/ARBs. Only 21 patients had proper antiPLA2R immunological monitoring. Conclusions One-fourth of patients with biopsy-proven MN as primary kidney disease recurred after KT, without a clear impact on graft survival. Spontaneous remission after rMN was associated with a higher exposure to tacrolimus before recurrence.12 página

Actividades en el medio natural

Compendio de artículos sobre el desarrollo de juegos y actividades físicas de carácter educativo en el medio natural. Se abordan aspectos tales como el desarrollo de las habilidades motrices básicas o la integración de la educación en valores y los temas transversales a través de la actividad física en el currículo educativo. Además se proponen actividades físicas a desarrollar en horario extraescolar tales como acampadas, viajes de turismo ecológico y deportivo, juegos de reto y aventura.AndalucíaBiblioteca de Educación del Ministerio de Educación, Cultura y Deporte; Calle San Agustín 5 -3 Planta; 28014 Madrid; Tel. +34917748000; [email protected]

Impacto de la COVID-19 en el tratamiento del infarto agudo de miocardio con elevación del segmento ST. La experiencia Española

The COVID-19 outbreak has had an unclear impact on the treatment and outcomes of patients with ST-segment elevation myocardial infarction (STEMI). The aim of this study was to assess changes in STEMI management during the COVID-19 outbreak. Using a multicenter, nationwide, retrospective, observational registry of consecutive patients who were managed in 75 specific STEMI care centers in Spain, we compared patient and procedural characteristics and in-hospital outcomes in 2 different cohorts with 30-day follow-up according to whether the patients had been treated before or after COVID-19. Suspected STEMI patients treated in STEMI networks decreased by 27.6% and patients with confirmed STEMI fell from 1305 to 1009 (22.7%). There were no differences in reperfusion strategy (> 94% treated with primary percutaneous coronary intervention in both cohorts). Patients treated with primary percutaneous coronary intervention during the COVID-19 outbreak had a longer ischemic time (233 [150-375] vs 200 [140-332] minutes, P < .001) but showed no differences in the time from first medical contact to reperfusion. In-hospital mortality was higher during COVID-19 (7.5% vs 5.1%; unadjusted OR, 1.50; 95%CI, 1.07-2.11; P < .001); this association remained after adjustment for confounders (risk-adjusted OR, 1.88; 95%CI, 1.12-3.14; P = .017). In the 2020 cohort, there was a 6.3% incidence of confirmed SARS-CoV-2 infection during hospitalization. The number of STEMI patients treated during the current COVID-19 outbreak fell vs the previous year and there was an increase in the median time from symptom onset to reperfusion and a significant 2-fold increase in the rate of in-hospital mortality. No changes in reperfusion strategy were detected, with primary percutaneous coronary intervention performed for the vast majority of patients. The co-existence of STEMI and SARS-CoV-2 infection was relatively infrequent.S

Multinational case-control study of risk factors for the development of late invasive pulmonary aspergillosis following kidney transplantation

OBJECTIVES: To assess the risk factors for development of late-onset invasive pulmonary aspergillosis (IPA) after kidney transplantation (KT). METHODS: We performed a multinational case-control study that retrospectively recruited 112 KT recipients diagnosed with IPA between 2000 and 2013. Controls were matched (1:1 ratio) by centre and date of transplantation. Immunosuppression-related events (IREs) included the occurrence of non-ventilator-associated pneumonia, tuberculosis, cytomegalovirus disease, and/or de novo malignancy. RESULTS: We identified 61 cases of late (>180 days after transplantation) IPA from 24 participating centres (accounting for 54.5% (61/112) of all cases included in the overall study). Most diagnoses (54.1% (33/61)) were established within the first 36 post-transplant months, although five cases occurred more than 10 years after transplantation. Overall mortality among cases was 47.5% (29/61). Compared with controls, cases were significantly older (p 0.010) and more likely to have pre-transplant chronic obstructive pulmonary disease (p 0.001) and a diagnosis of bloodstream infection (p 0.016) and IRE (p <0.001) within the 6 months prior to the onset of late IPA. After multivariate adjustment, previous occurrence of IRE (OR 19.26; 95% CI 2.07-179.46; p 0.009) was identified as an independent risk factor for late IPA. CONCLUSION: More than half of IPA cases after KT occur beyond the sixth month, with some of them presenting very late. Late IPA entails a poor prognosis. We identified some risk factors that could help the clinician to delimit the subgroup of KT recipients at the highest risk for late IPA

International Ignatian Reconciliation Conference: From crisis and confrontation to healing and forgiveness, how is reconciliation possible?

El compromiso de la Compañía de Jesús en el quehacer universitario se expresa en el deseo de contribuir efectivamente a hacer posible una vida digna, plena, para todos y cada uno de los seres humanos, en el presente y en el futuro. Para lograr una vida digna, una vida plena, se requiere la reconciliación. Por ello, la Universidad jesuita debe ser una fuente de vida, comprometida a fondo en los procesos de reconciliación. La Universidad Pontificia Comillas y la Pontificia Universidad Javeriana trabajaron bajo la orientación y el estímulo del padre Michael J. Garanzini, S. J. en la organización de la Conferencia Internacional de Reconciliación Ignaciana de la Crisis y el Enfrentamiento a la Sanación y el Perdón: ¿Cómo es Posible la Reconciliación?, que se realizó del 10 al 12 de mayo de 2021, en modalidad combinada (presencial y remota), desde Madrid. En esta, además de abordajes conceptuales sobre la reconciliación, se presentaron experiencias consolidadas en territorios o con comunidades específicas de construcción de paz y reconciliación de instituciones vinculadas a la Compañía de Jesús. Las memorias de la Conferencia que aquí presentamos tienen el fin de contribuir a que las conversaciones de perdón se den y se multipliquen, de modo que la reconstrucción del tejido social deje de ser una utopía para convertirse en una posibilidad palpable. Sin más, esta Conferencia fue el resultado de esa unión por la que tanto propende la reconciliación, pues no debemos olvidar que parte del proceso para llegar a ella nace del amor y de una meta por trascender todo aquello que nos divide y que, en este caso, se hace desde unas universidades comprometidas y de la mano del legado espiritual de san Ignacio.The commitment of the Society of Jesus in university work is expressed in the desire to effectively contribute to making possible a dignified, full life for each and every one of the human beings, in the present and in the future. To achieve a dignified life, a full life, reconciliation is required. For this reason, the Jesuit University must be a source of life, fully committed to reconciliation processes. Comillas Pontifical University and Javeriana Pontifical University worked under the guidance and encouragement of Father Michael J. Garanzini, S.J. in organizing the International Conference on Ignatian Reconciliation from Crisis and Confrontation to Healing and Forgiveness: How is Possible Reconciliation?, which took place from May 10 to 12, 2021, in a combined modality (face-to-face and remote), from Madrid. In this, in addition to conceptual approaches on reconciliation, consolidated experiences in territories or with specific communities of peacebuilding and reconciliation of institutions linked to the Society of Jesus were presented. The Conference proceedings that we present here have the purpose of contributing to the conversations of forgiveness occurring and multiplying, so that the reconstruction of the social fabric ceases to be a utopia and becomes a palpable possibility. Without further ado, this Conference was the result of that union for which reconciliation tends so much, because we must not forget that part of the process to reach it is born of love and of a goal to transcend everything that divides us and that, in this case, it is done from committed universities and hand in hand with the spiritual legacy of Saint Ignatius.Madri

Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial

Background: Additional safe and efficacious vaccines are needed to control the COVID-19 pandemic. We aimed to analyse the efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate. Methods: HERALD is a randomised, observer-blinded, placebo-controlled, phase 2b/3 clinical trial conducted in 47 centres in ten countries in Europe and Latin America. By use of an interactive web response system and stratification by country and age group (18–60 years and ≥61 years), adults with no history of virologically confirmed COVID-19 were randomly assigned (1:1) to receive intramuscularly either two 0·6 mL doses of CVnCoV containing 12 μg of mRNA or two 0·6 mL doses of 0·9% NaCl (placebo) on days 1 and 29. The primary efficacy endpoint was the occurrence of a first episode of virologically confirmed symptomatic COVID-19 of any severity and caused by any strain from 15 days after the second dose. For the primary endpoint, the trial was considered successful if the lower limit of the CI was greater than 30%. Key secondary endpoints were the occurrence of a first episode of virologically confirmed moderate-to-severe COVID-19, severe COVID-19, and COVID-19 of any severity by age group. Primary safety outcomes were solicited local and systemic adverse events within 7 days after each dose and unsolicited adverse events within 28 days after each dose in phase 2b participants, and serious adverse events and adverse events of special interest up to 1 year after the second dose in phase 2b and phase 3 participants. Here, we report data up to June 18, 2021. The study is registered at ClinicalTrials.gov, NCT04652102, and EudraCT, 2020–003998–22, and is ongoing. Findings: Between Dec 11, 2020, and April 12, 2021, 39 680 participants were enrolled and randomly assigned to receive either CVnCoV (n=19 846) or placebo (n=19 834), of whom 19 783 received at least one dose of CVnCoV and 19 746 received at least one dose of placebo. After a mean observation period of 48·2 days (SE 0·2), 83 cases of COVID-19 occurred in the CVnCoV group (n=12 851) in 1735·29 person-years and 145 cases occurred in the placebo group (n=12 211) in 1569·87 person-years, resulting in an overall vaccine efficacy against symptomatic COVID-19 of 48·2% (95·826% CI 31·0–61·4; p=0·016). Vaccine efficacy against moderate-to-severe COVID-19 was 70·7% (95% CI 42·5–86·1; CVnCoV 12 cases in 1735·29 person-years, placebo 37 cases in 1569·87 person-years). In participants aged 18–60 years, vaccine efficacy against symptomatic disease was 52·5% (95% CI 36·2–64·8; CVnCoV 71 cases in 1591·47 person-years, placebo, 136 cases in 1449·23 person-years). Too few cases occurred in participants aged 61 years or older (CVnCoV 12, placebo nine) to allow meaningful assessment of vaccine efficacy. Solicited adverse events, which were mostly systemic, were more common in CVnCoV recipients (1933 [96·5%] of 2003) than in placebo recipients (1344 [67·9%] of 1978), with 542 (27·1%) CVnCoV recipients and 61 (3·1%) placebo recipients reporting grade 3 solicited adverse events. The most frequently reported local reaction after any dose in the CVnCoV group was injection-site pain (1678 [83·6%] of 2007), with 22 grade 3 reactions, and the most frequently reported systematic reactions were fatigue (1603 [80·0%] of 2003) and headache (1541 [76·9%] of 2003). 82 (0·4%) of 19 783 CVnCoV recipients reported 100 serious adverse events and 66 (0·3%) of 19 746 placebo recipients reported 76 serious adverse events. Eight serious adverse events in five CVnCoV recipients and two serious adverse events in two placebo recipients were considered vaccination-related. None of the fatal serious adverse events reported (eight in the CVnCoV group and six in the placebo group) were considered to be related to study vaccination. Adverse events of special interest were reported for 38 (0·2%) participants in the CVnCoV group and 31 (0·2%) participants in the placebo group. These events were considered to be related to the trial vaccine for 14 (<0·1%) participants in the CVnCoV group and for five (<0·1%) participants in the placebo group. Interpretation: CVnCoV was efficacious in the prevention of COVID-19 of any severity and had an acceptable safety profile. Taking into account the changing environment, including the emergence of SARS-CoV-2 variants, and timelines for further development, the decision has been made to cease activities on the CVnCoV candidate and to focus efforts on the development of next-generation vaccine candidates. Funding: German Federal Ministry of Education and Research and CureVac